Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AbGn-107 |
| Synonyms | |
| Therapy Description |
AbGn-107 is an antibody drug conjugate comprised of a monoclonal antibody that targets AG7 linked to a proprietary cytotoxic therapy, which binds to cancer cells expressing AG7 and potentially induces cell death (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AbGn-107 | AbGn 107 | AbGn-107 is an antibody drug conjugate comprised of a monoclonal antibody that targets AG7 linked to a proprietary cytotoxic therapy, which binds to cancer cells expressing AG7 and potentially induces cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Terminated | USA | 1 |